Isotopes for Hope
In 2024, the CNIC launched the Isotopes for Hope Podcast, hosted by our Chair, James Scongack. This multi-part series highlights Canadian leaders in the country’s isotope and cancer care sector who are contributing to Canada’s leadership role in fighting cancer. We aim to feature unique stories and perspectives about the importance of isotopes from industry leaders across the country.
Isotopes for Hope Podcast - Trailer
The next phase of the campaign will reach a new medium with the release of the Isotopes for Hope Podcast series. The Isotopes for Hope Podcast will be a multi-part series that highlights Canadian leaders in the country's isotope and cancer care sector who are contributing to Canada's leadership role in fighting cancer. Each episode will feature a 20-30 minute conversational-style interview hosted by CNIC Chair James Scongack.
While this podcast aims to frame the industry’s future in this area, we also feature unique stories and perspectives about the importance of isotopes from current industry leaders.
Listen to the Isotopes for Hope Podcast on Apple Podcasts, Spotify, and Youtube.Show More

The next phase of the campaign will reach a new medium with the release of the Isotopes for Hope Podcast series. The Isotopes for Hope Podcast will be a multi-part series that highlights Canadian leaders in the country's isotope and cancer care sector who are contributing to Canada's leadership role in fighting cancer. Each episode will feature a 20-30 minute conversational-style interview hosted by CNIC Chair James Scongack.
While this podcast aims to frame the industry’s future in this area, we also feature unique stories and perspectives about the importance of isotopes from current industry leaders.
Listen to the Isotopes for Hope Podcast on Apple Podcasts, Spotify, and Youtube.Show More

In the first episode of the Podcast series, Chair James Scongack is joined by Dr. Mark Greenberg, co-founder of the Pediatric Oncology Group of Ontario (POGO) and Dr. David Hodgson, the Medical Director of POGO. POGO champions childhood cancer care, works to remove barriers to access, and improve patient and family education, while acting as the official advisor to Ontario’s Ministry of Health on children’s cancer control and treatment.Show More

In this episode, CNIC Chair James Scongack is joined by Kathryn Hayashi, President & CEO of TRIUMF Innovations, and Executive Committee Co-Chair of the Canadian Medical Isotope Ecosystem (CMIE) initiative. TRIUMF Innovations is the business interface and commercialization arm, connecting TRIUMF, Canada's particle accelerator centre, to the private sector via industry partnerships, licensing, and company creation.Show More

In this episode, CNIC Chair James Scongack is joined by Riaz Bandali, President of Nordion. Nordion is the global leader in the provision of Cobalt 60, which is a critical radioisotope used to sterilize 30% of the world’s single use medical devices, and it is also used for the treatment of brain and breast cancer.Show More

In this episode, CNIC Chair James Scongack is joined by Mike Rencheck, President and CEO of Bruce Power, Canada’s only private sector nuclear generator, annually producing 30% of Ontario’s power as well as a significant portion of the global supply of cobalt-60 and lutetium-177.Show More

In this episode, CNIC Chair James Scongack is joined by Dr. Arjun Sahgal, Chief of the Department of Radiation Oncology at the University of Toronto Sunnybrook Odette Cancer Centre, and Shannon LaHay, CEO of the Brain Tumour Foundation of Canada. Join us for a conversation about how isotope are used to diagnose and treat brain tumours and brain metastases, offering promising results for patients.Show More

In this episode, CNIC Chair James Scongack is joined by David Harris, President & CEO of Kinectrics, and Dr. Travis Besanger, Senior Business & Technical Director of Medical Isotopes at Kinectrics. Kinectrics and Framatome together form a joint venture called IsoGen that has implemented an Isotope Production System at Bruce Power. The IPS is the world’s first commercial scale source of lutetium-177 produced by a power reactor and the first commercial stable isotope enrichment platform for the production of ytterbium-176 in North America.Show More

In this episode, CNIC Chair James Scongack is joined by Dr. Karin Stephenson, Director of Research and Education support for Nuclear Operations and Facilities at McMaster University. McMaster University is home to Canada's most powerful neutron source, and is a global leader in the production of iodine-125 and holmium-166, used to treat cancer patients around the world.Show More

In this episode, CNIC Chair James Scongack is joined by Steffen Schuster, CEO of ITM Isotope Technologies Munich. Based in Germany but with several partnerships with Canadian companies like Bruce Power, IsoGen, and more recently Canadian Nuclear Laboratories through new venture Actineer, ITM is a global leader in the development, production and global supply of targeted diagnostic and therapeutic radioisotopes for use in cancer treatment.Show More

In this episode, CNIC Chair James Scongack is joined by Robert Kamen, founding President of South West Exposures (SWE). SWE is an industry leader in the shielding and packaging of medical isotopes for diagnostic and therapeutic applications, helping to make just-in-time delivery of isotopes safe and timely.Show More

In this episode, CNIC Chair James Scongack is joined by Dr. Jonathan Cirtain, Senior VP and Chief Development Officer of BWX Technologies (BWXT) and President & CEO of BWXT Medical Ltd. BWXT Medical is an experienced manufacturer and supplier of both isotope technologies and critical medical isotopes and radiopharmaceuticals for research, diagnostic and therapeutic use.Show More

In this episode, CNIC Chair James Scongack is joined by Ram Mullur of Canadian Nuclear Laboratories, who highlights CNL as a Canadian gem of research and innovation that put Canada at the forefront at a time when the global isotope industry was in its formative stages. Through a new partnership with Germany's ITM, CNL has formed Actineer, which will focus on expanding production of the highly-promising radiotheranostic isotope actinium-225 here in Canada.Show More

This episode features Dr. Rebecca Wong and Dr. Patrick Veit-Haibach of Toronto's University Health Network who share their perspectives on current and upcoming clinical trials using radiotheranostic drugs to improve patient outcomes. Radiotheranostics can both diagnose and treat cancers with far fewer side-effects from traditional treatments like chemotherapy or surgery, and offer promising results through personalized medicine. With Canada’s leading production sector and infrastructure, we have a significant opportunity to continue to lead in this space with strategic investments and policies across the supply chain.Show More

In this episode, CNIC Chair James Scongack is joined by Member of Parliament Pam Damoff, who has been a champion for the Canadian isotope industry throughout her career. Join James and Pam as they discuss how collaboration between various levels of government, across party lines, and internationally is essential to improving access to nuclear medicine.Show More

In this episode, Gary Rose of AtkinsRéalis explores how our CANDU reactors are an important asset for Canada's medical isotope future as we continue to leverage our power reactor fleet to provide high volumes of isotopes. Our CANDU reactors have given us the ability to not only produce electricity, but to become a high volume, reliable source for medical isotopes. In the future, AtkinsRéalis is working to make it even easier to produce medical isotopes, using purpose-built access ports to take our production to the next level through the design of a new MONARK CANDU reactor.Show More

Rachel Sumner, CEO of Talent joins Chair of the CNIC, James Scongack for a discussion on workforce development and planning for the Canadian medical isotope industry. It's the capability of people in our sector that makes all the difference. It's what gives Canada our competitive advantage and the confidence to know that we can continue to play a critical global role in the production, use, and deployment of medical isotopes for decades to come.Show More

Join CNIC Chair James Scongack for this exciting episode with John Burta of Laurentis Energy Partners and Dr. Wayne Mullett of Boston Scientific who discuss a new partnership to use OPG's Darlington Facility to irradiate yttrium-90 microspheres, offering new hope to patients with liver cancer. The work being done in Canada to use commercial CANDU reactors to shore up supply and add reliability to the pipeline puts us in a position to truly lead the global fight against cancer.Show More

This episode features Dale Schick-Martin of the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, a Canadian gem for research in nuclear materials. The Centre operates the Saskatchewan Cyclotron Facility, which provides critical just-in-time isotopes to hospitals in the Saskatchewan and surrounding provinces. Cyclotrons, like the one at the Fedoruk Centre, are an essential piece of Canada’s isotope infrastructure, providing another form of energy that's required to supply lifesaving isotopes directly to the hospitals that need them.Show More

This episode features Mayor Ian Boddy of Owen Sound and Mayor Adrian Foster of Clarington. These leaders highlight the role that nuclear isotope innovation plays in their regions and discuss their work in support of the regional isotope coalitions and alliances in their communities, the Southwestern Ontario Isotope Coalition (SOIC) and the Central and Eastern Ontario Isotope Alliance (CEOIA).
The SOIC and CEOIA are two regional initiatives driven by cooperation between municipal governments and local leaders in the private sector. These organizations demonstrate the power of regional networks in attracting investment, strengthening supply chains, and advancing Canada’s isotope leadership.Show More

This episode features Lisa Stevens, Director of Programme of Action for Cancer Therapy (PACT) at the International Atomic Energy Agency (IAEA). Lisa joins James for a discussion about the important work that the IAEA leads, its Rays of Hope initiative, and the new partnership between the CNIC and the IAEA in support of the initiative.
In 2022, the International Atomic Energy Agency (IAEA) launched Rays of Hope, an initiative aimed at addressing disparities in radiation medicine for cancer treatment in low- and middle-income countries. Through partnerships with governments, international financial institutions, and the private sector, Rays of Hope helps to save lives by increasing access to radiotherapy infrastructure and diagnostic imaging used in cancer care.Show More
In March 2023, CNIC launched its Isotopes for Hope campaign, focused on the goal of expanding Canada’s global leadership in the development, supply, and use of medical isotopes and raising awareness for the pivotal role that isotopes play in modern medicine.
As part of Phase 1 of the Isotopes for Hope campaign, CNIC released a new report entitled “Isotopes for Hope: Canadian Leadership Needed Now More Than Ever.” The report offers updated market figures, emerging trends for isotopes, and opportunities for Canada in the global market.
The global market for nuclear medicine is anticipated to reach up to $33 billion US by 2031. Given the significant opportunities for Canada to act as a global leader in the fight against cancer, the Isotopes for Hope campaign is built upon an ambitious vision of doubling Canada’s production of medical isotopes by 2030 to meet rising need.
Furthering CNIC’s advocacy efforts through the Isotopes for Hope campaign, CNIC released “Isotopes for Hope: Update on Recommendations” in October 2023, which serves as an update to CNIC’s advocacy efforts through the campaign. The report summarizes the progress made on each recommendation, identifies ongoing industry challenges, and identifies advocacy focus areas for 2024, all to maintain momentum and continue working toward the goal of doubling production by 2030.
An update on the Isotopes for Hope report is currently in the works, with its release planned later in 2025.


The campaign also seeks to identify barriers to unleashing Canada’s true isotope potential and commits to working alongside governments to develop solutions and encourage support for the industry. The Isotopes for Hope report contains several recommendations for government to best support the growing industry through policy, financial, and regulatory measures.